Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements.

Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, Duployez N, Tanguy-Schmidt A, Tamburini J, Maury S, Doré E, Himberlin C, Duclos C, Chevallier P, Rousselot P, Bonifacio M, Cavé H, Baruchel A, Dombret H, Soulier J, Landman-Parker J, Boissel N, Clappier E.

Blood. 2019 Aug 21. pii: blood.2019001244. doi: 10.1182/blood.2019001244. [Epub ahead of print] No abstract available.

PMID:
31434701
2.

I feel pain here!

Landman-Parker J.

Arch Pediatr. 2019 Jul;26(5):252-253. doi: 10.1016/j.arcped.2019.05.003. Epub 2019 Jul 4. No abstract available.

PMID:
31281040
3.

Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.

Rigaud C, Auperin A, Jourdain A, Haouy S, Couec ML, Aladjidi N, Gandemer V, Lambliotte A, Plat G, Landman-Parker J, Michon J, Leblanc T, Patte C, Minard-Colin V.

Pediatr Blood Cancer. 2019 Sep;66(9):e27873. doi: 10.1002/pbc.27873. Epub 2019 Jun 17.

PMID:
31207026
4.

Neurological Involvement in Childhood Evans Syndrome.

Pincez T, Neven B, Le Pointe HD, Varlet P, Fernandes H, Gareton A, Leverger G, Leblanc T, Chambost H, Michel G, Pasquet M, Millot F, Hermine O, Mathian A, Hully M, Zephir H, Hamidou M, Durand JM, Perel Y, Landman-Parker J, Rieux-Laucat F, Aladjidi N.

J Clin Immunol. 2019 Feb;39(2):171-181. doi: 10.1007/s10875-019-0594-3. Epub 2019 Jan 22.

PMID:
30671780
5.

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.

Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG.

J Immunother Cancer. 2018 Dec 27;6(1):159. doi: 10.1186/s40425-018-0482-z.

6.

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L.

Lancet Haematol. 2018 Oct;5(10):e450-e461. doi: 10.1016/S2352-3026(18)30153-4.

PMID:
30290902
7.

Subtotal and total splenectomy for hereditary pyropoikilocytosis: Benefits and outcomes.

Pincez T, Guitton C, Landman-Parker J, Brousse V, Gauthier F, Da Costa L, Ghazal K, Dufillot D, Tchernia G, Picard V, Garçon L.

Am J Hematol. 2018 Oct;93(10):E340-E342. doi: 10.1002/ajh.25223. Epub 2018 Sep 26. No abstract available.

PMID:
30035308
8.

18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?

Georgi TW, Kluge R, Kurch L, Chavdarova L, Hasenclever D, Stoevesandt D, Pelz T, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Fosså A, Balwierz W, Attarbaschi A, Ammann RA, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Baumann J, Körholz D, Sabri O, Mauz-Körholz C.

J Nucl Med. 2018 Oct;59(10):1524-1530. doi: 10.2967/jnumed.117.205633. Epub 2018 Apr 13.

PMID:
29653979
9.

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

Gore L, Kearns PR, de Martino ML, Lee, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM.

J Clin Oncol. 2018 May 1;36(13):1330-1338. doi: 10.1200/JCO.2017.75.9597. Epub 2018 Mar 2.

10.

Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations.

Besnard C, Levy E, Aladjidi N, Stolzenberg MC, Magerus-Chatinet A, Alibeu O, Nitschke P, Blanche S, Hermine O, Jeziorski E, Landman-Parker J, Leverger G, Mahlaoui N, Michel G, Pellier I, Suarez F, Thuret I, de Saint-Basile G, Picard C, Fischer A, Neven B, Rieux-Laucat F, Quartier P; Members of the French reference center for pediatric autoimmune cytopenias (CEREVANCE).

Clin Immunol. 2018 Mar;188:52-57. doi: 10.1016/j.clim.2017.12.009. Epub 2018 Jan 10.

PMID:
29330115
11.

Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia.

Cahu X, Calvo J, Poglio S, Prade N, Colsch B, Arcangeli ML, Leblanc T, Petit A, Baleydier F, Baruchel A, Landman-Parker J, Junot C, Larghero J, Ballerini P, Delabesse E, Uzan B, Pflumio F.

Blood Adv. 2017 Sep 8;1(20):1760-1772. doi: 10.1182/bloodadvances.2017004960. eCollection 2017 Sep 12.

12.

Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia.

Renou L, Boelle PY, Deswarte C, Spicuglia S, Benyoucef A, Calvo J, Uzan B, Belhocine M, Cieslak A, Landman-Parker J, Baruchel A, Asnafi V, Pflumio F, Ballerini P, Naguibneva I.

Blood Adv. 2017 May 4;1(12):733-747. doi: 10.1182/bloodadvances.2017005538. eCollection 2017 May 9.

13.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V; French Acute Lymphoblastic Leukemia Study Group (FRALLE).

Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19.

14.

Redelivering Information to Young Adults and Adolescents Treated for Cancer During Childhood.

Landman-Parker J.

J Oncol Pract. 2017 Aug;13(8):467-469. doi: 10.1200/JOP.2017.022608. Epub 2017 Jul 13. No abstract available.

PMID:
28704123
15.

Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.

Shankar AG, Roques G, Kirkwood AA, Lambilliotte A, Freund K, Leblanc T, Hayward J, Abbou S, Ramsay AD, Schmitt C, Gorde-Grosjean S, Pacquement H, Haouy S, Boudjemaa S, Aladjidi N, Hall GW, Landman-Parker J.

Br J Haematol. 2017 Apr;177(1):106-115. doi: 10.1111/bjh.14518. Epub 2017 Feb 21.

PMID:
28220934
16.

Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement.

Flerlage JE, Kelly KM, Beishuizen A, Cho S, De Alarcon PA, Dieckmann U, Drachtman RA, Hoppe BS, Howard SC, Kaste SC, Kluge R, Kurch L, Landman-Parker J, Lewis J, Link MP, McCarten K, Punnett A, Stoevesandt D, Voss SD, Wallace WH, Mauz-Körholz C, Metzger ML.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26421. Epub 2017 Jan 18.

PMID:
28097818
17.

Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines.

Seror E, Donadieu J, Pacquement H, Abbou S, Lambilliotte A, Schell M, Curtillet C, Gandemer V, Pasquet M, Aladjidi N, Lutz P, Schmitt C, Deville A, Minckes O, Vanier JP, Armari-Alla C, Thomas C, Gorde-Grosjean S, Millot F, Blouin P, Garnier N, Coze C, Devoldere C, Reguerre Y, Helfre S, Claude L, Clavel J, Oberlin O, Landman-Parker J, Leblanc T.

Pediatr Hematol Oncol. 2016 Oct - Nov;33(7-8):423-437.

PMID:
27960645
18.

Reply.

Jorgov L, Montravers F, Balogova S, Landman-Parker J, Talbot JN.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):172. No abstract available.

PMID:
27730331
19.

Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia.

Poglio S, Lewandowski D, Calvo J, Caye A, Gros A, Laharanne E, Leblanc T, Landman-Parker J, Baruchel A, Soulier J, Ballerini P, Clappier E, Pflumio F.

Oncotarget. 2016 Jul 5;7(27):41599-41611. doi: 10.18632/oncotarget.9313.

20.

Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.

Jorgov L, Montravers F, Balogova S, Ragu C, Pacquement H, Leblanc T, Abbou S, Ducou-Lepointe H, Landman-Parker J, Talbot JN.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1220-30. doi: 10.1007/s00259-015-3280-6. Epub 2015 Dec 14.

PMID:
26660144
21.

[Multidisciplinarity, education, and training in pediatric oncology-hematology].

Vassal G, Landman-Parker J, Baruchel A, Bergeron C, Rubie H, Coze C, Chastagner P, Leverger G, Bertrand Y, Valteau-Couanet D, Michon J, Couanet D, Rivière AM, Avenell D, Pérel Y, Doz F.

Arch Pediatr. 2015 Dec;22(12):1217-22. doi: 10.1016/j.arcped.2015.09.012. Epub 2015 Nov 18. Review. French.

PMID:
26604021
22.

Long-term outcome of children with pediatric-onset cutaneous and visceral polyarteritis nodosa.

Merlin E, Mouy R, Pereira B, Mouthon L, Bourmaud A, Piette JC, Landman-Parker J, Chellun P, Layadi M, Thomas C, Guillevin L, Prieur AM, Quartier P.

Joint Bone Spine. 2015 Jul;82(4):251-7. doi: 10.1016/j.jbspin.2015.01.007. Epub 2015 Apr 15.

PMID:
25887252
23.

Rapid childhood T-ALL growth in xenograft models correlates with mature phenotype and NF-κB pathway activation but not with poor prognosis.

Poglio S, Cahu X, Uzan B, Besnard-Guérin C, Lapillonne H, Leblanc T, Baruchel A, Landman-Parker J, Petit A, Baleydier F, Amsellem S, Baud V, Ballerini P, Pflumio F.

Leukemia. 2015 Apr;29(4):977-80. doi: 10.1038/leu.2014.317. Epub 2014 Nov 5. No abstract available.

PMID:
25371179
24.

[Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].

Gorde-Grosjean S, Guimard G, Lambilliotte A, Coulomb-Lhermine A, Montravers F, Landman-Parker J.

Bull Cancer. 2014 Sep;101(9):881-90. doi: 10.1684/bdc.2014.2021. Review. French.

PMID:
25296072
25.

Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression.

Uzan B, Poglio S, Gerby B, Wu CL, Gross J, Armstrong F, Calvo J, Cahu X, Deswarte C, Dumont F, Passaro D, Besnard-Guérin C, Leblanc T, Baruchel A, Landman-Parker J, Ballerini P, Baud V, Ghysdael J, Baleydier F, Porteu F, Pflumio F.

EMBO Mol Med. 2014 Jun;6(6):821-34. doi: 10.1002/emmm.201303286. Epub 2014 Apr 6.

26.

qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.

Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, Landman-Parker J, Moryl-Bujakowska A, Cepelová M, Karlén J, Álvarez Fernández-Teijeiro A, Attarbaschi A, Fosså A, Pears J, Hraskova A, Bergsträsser E, Beishuizen A, Uyttebroeck A, Schomerus E, Sabri O, Körholz D, Kluge R.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1301-8. doi: 10.1007/s00259-014-2715-9. Epub 2014 Mar 7.

PMID:
24604592
27.

SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.

Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, Lapillonne H, Deswarte C, Goussard P, Laurendeau I, Uzan B, Pflumio F, Brizard F, Vabres P, Naguibvena I, Fasola S, Millot F, Porteu F, Vidaud D, Landman-Parker J, Ballerini P.

Oncogene. 2015 Jan 29;34(5):631-8. doi: 10.1038/onc.2013.587. Epub 2014 Jan 27.

PMID:
24469042
28.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H.

Eur J Cancer. 2014 Jan;50(1):170-7. doi: 10.1016/j.ejca.2013.08.012. Epub 2013 Sep 7.

PMID:
24021349
29.

Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study.

Chappuy H, Bouazza N, Minard-Colin V, Patte C, Brugières L, Landman-Parker J, Auvrignon A, Davous D, Pacquement H, Orbach D, Tréluyer JM, Doz F.

BMJ Open. 2013 May 28;3(5). pii: e002733. doi: 10.1136/bmjopen-2013-002733.

30.

Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.

Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, Guégan J, Rivera-Munoz P, Bluteau O, Mabialah V, Diop M, Wen Q, Petit A, Bauchet AL, Reinhardt D, Bornhauser B, Gautheret D, Lecluse Y, Landman-Parker J, Radford I, Vainchenker W, Dastugue N, de Botton S, Dessen P, Bourquin JP, Crispino JD, Ballerini P, Bernard OA, Pflumio F, Mercher T.

J Exp Med. 2012 Oct 22;209(11):2017-31. doi: 10.1084/jem.20121343. Epub 2012 Oct 8.

31.

Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).

Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A, Schell M, Dommange F, Munzer M, Paillard C, Schmitt C, Lutz P, Edan C, Ansoborlo S, Stephan JL, Michel G, Thomas C, Perel Y, Robert A, Landman-Parker J.

Br J Haematol. 2012 Sep;158(5):649-56. doi: 10.1111/j.1365-2141.2012.09199.x. Epub 2012 Jul 4.

PMID:
22757721
32.

Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report.

Shankar A, Hall GW, Gorde-Grosjean S, Hasenclever D, Leblanc T, Hayward J, Lambilliotte A, Daw S, Perel Y, McCarthy K, Lejars O, Coulomb A, Oberlin WO, Wallace WH, Landman-Parker J.

Eur J Cancer. 2012 Jul;48(11):1700-6. doi: 10.1016/j.ejca.2011.10.018. Epub 2011 Nov 15.

PMID:
22093944
33.

Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia.

Fresneau B, Petit A, Courcoux MF, Tabone MD, Auvrignon A, Landman-Parker J, Leverger G.

Am J Hematol. 2011 Sep;86(9):785-7. doi: 10.1002/ajh.22081. Epub 2011 Jul 28. No abstract available.

34.

Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations.

Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S, Soulier J, Boissel N, Leblanc T, Baruchel A, Landman-Parker J, Roméo PH, Ballerini P, Pflumio F.

Leukemia. 2011 Aug;25(8):1249-58. doi: 10.1038/leu.2011.93. Epub 2011 May 13.

PMID:
21566655
35.

Contribution of HLA-A/B/C/DRB1/DQB1 common haplotypes to donor search outcome in unrelated hematopoietic stem cell transplantation.

Pédron B, Guérin-El Khourouj V, Dalle JH, Ouachée-Chardin M, Yakouben K, Corroyez F, Auvrignon A, Petit A, Landman-Parker J, Leverger G, Baruchel A, Sterkers G.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1612-8. doi: 10.1016/j.bbmt.2011.03.009. Epub 2011 Apr 12.

36.

[Hodgkin disease and autoimmunity in children: 11 case reports].

Jarrassé C, Pagnier A, Edan C, Landman-Parker J, Mazingue F, Mansuy L, Bertrand Y, Paillard C, Pellier I, Margueritte G, Plantaz D.

Arch Pediatr. 2011 Apr;18(4):376-82. doi: 10.1016/j.arcped.2011.01.025. French.

PMID:
21397466
37.

Childhood Hodgkin's lymphoma, non-Hodgkin's lymphoma and factors related to the immune system: the Escale Study (SFCE).

Rudant J, Orsi L, Monnereau A, Patte C, Pacquement H, Landman-Parker J, Bergeron C, Robert A, Michel G, Lambilliotte A, Aladjidi N, Gandemer V, Lutz P, Margueritte G, Plantaz D, Méchinaud F, Hémon D, Clavel J.

Int J Cancer. 2011 Nov 1;129(9):2236-47. doi: 10.1002/ijc.25862. Epub 2011 Apr 1.

38.

[Is there a risk of steroid-induced adrenal deficit after induction treatment of acute lymphoblastic leukemia?].

Bélien-Pallet V, Cabrol S, Fasola S, Petit A, Landman-Parker J, Auvrignon A, Leverger G.

Arch Pediatr. 2010 Dec;17(12):1637-44. doi: 10.1016/j.arcped.2010.09.001. Epub 2010 Oct 12. French.

PMID:
20943354
39.

[New insights into acute lymphoblastic leukemia].

Landman-Parker J, Pagès P, Petit A, Fasola S, Leverger G.

Bull Acad Natl Med. 2009 Oct;193(7):1501-7. Review. French.

PMID:
20669631
40.

[Inherited thrombocytopenias].

Leverger G, Petit A, Fasola S, Landman-Parker J, Favier R.

Arch Pediatr. 2010 Aug;17(8):1185-91. doi: 10.1016/j.arcped.2010.04.022. Epub 2010 Jun 8. French.

PMID:
20570496
41.

Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.

Rubie H, Geoerger B, Frappaz D, Schmitt A, Leblond P, Ndiaye A, Aerts I, Le Deley MC, Gentet JC, Paci A, Chastagner P, Dias N, Djafari L, Pasquet M, Chatelut E, Landman-Parker J, Corradini N, Vassal G.

Eur J Cancer. 2010 Oct;46(15):2763-70. doi: 10.1016/j.ejca.2010.05.004. Epub 2010 Jun 16.

PMID:
20558056
42.

Optimized gene transfer into human primary leukemic T cell with NOD-SCID/leukemia-initiating cell activity.

Gerby B, Armstrong F, de la Grange PB, Medyouf H, Calvo J, Verhoeyen E, Cosset FL, Bernstein I, Amselem S, Boissel N, Dombret H, Leblanc T, Baruchel A, Landman-Parker J, Ballerini P, Pflumio F.

Leukemia. 2010 Mar;24(3):646-9. doi: 10.1038/leu.2009.235. Epub 2009 Nov 19. No abstract available.

PMID:
19924146
43.

Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia.

Lapillonne H, Llopis L, Auvrignon A, Renneville A, Labopin M, Mazingue F, Perot C, Lai JL, Philippe N, Ballerini P, Zurawski V, Adam M, Douay L, Leverger G, Landman-Parker J, Preudhomme C.

Leukemia. 2010 Jan;24(1):205-9. doi: 10.1038/leu.2009.172. Epub 2009 Sep 17. No abstract available.

PMID:
19759559
44.

SPRED1 disorder and predisposition to leukemia in children.

Pasmant E, Ballerini P, Lapillonne H, Perot C, Vidaud D, Leverger G, Landman-Parker J.

Blood. 2009 Jul 30;114(5):1131. doi: 10.1182/blood-2009-04-218503. No abstract available.

45.

[New insights in Hodgkin's lymphoma biology].

Landman-Parker J, Gorde-Grosjean S.

Arch Pediatr. 2009 Jun;16(6):667-8. doi: 10.1016/S0929-693X(09)74105-3. French. No abstract available.

PMID:
19541123
46.

WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?

Corbin M, de Reyniès A, Rickman DS, Berrebi D, Boccon-Gibod L, Cohen-Gogo S, Fabre M, Jaubert F, Faussillon M, Yilmaz F, Sarnacki S, Landman-Parker J, Patte C, Schleiermacher G, Antignac C, Jeanpierre C.

Genes Chromosomes Cancer. 2009 Sep;48(9):816-27. doi: 10.1002/gcc.20686.

PMID:
19530245
47.

SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.

Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P, Ballerini P, Cartault F, Barbarot S, Landman-Parker J, Soufir N, Parfait B, Vidaud M, Wolkenstein P, Vidaud D, France RN.

J Med Genet. 2009 Jul;46(7):425-30. doi: 10.1136/jmg.2008.065243. Epub 2009 Apr 14.

48.

NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity.

Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M, Boissel N, Dombret H, Baruchel A, Landman-Parker J, Roméo PH, Ballerini P, Pflumio F.

Blood. 2009 Feb 19;113(8):1730-40. doi: 10.1182/blood-2008-02-138172. Epub 2008 Nov 4.

49.

Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.

Ballerini P, Landman-Parker J, Cayuela JM, Asnafi V, Labopin M, Gandemer V, Perel Y, Michel G, Leblanc T, Schmitt C, Fasola S, Hagemejier A, Sigaux F, Auclerc MF, Douay L, Leverger G, Baruchel A.

Haematologica. 2008 Nov;93(11):1658-65. doi: 10.3324/haematol.13291. Epub 2008 Oct 2.

50.

Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.

Geoerger B, Doz F, Gentet JC, Mayer M, Landman-Parker J, Pichon F, Chastagner P, Rubie H, Frappaz D, Le Bouil A, Gupta S, Vassal G.

J Clin Oncol. 2008 Sep 20;26(27):4394-400. doi: 10.1200/JCO.2008.16.7585.

PMID:
18802151

Supplemental Content

Loading ...
Support Center